|Title:||Administration of intravenous ibuprofen|
|Abstract:||An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.|
|Inventor(s):||Pavliv; Leo (Cary, NC)|
|Assignee:||Cumberland Pharmaceuticals (Nashville, TN)|
1. A method for reducing surgical pain in human patients, consisting of (i) treating post-surgical pain by administering a first dose of intravenous ibuprofen solution
in an amount of about 800 mg prior to the start of surgery on the patients, (ii) intravenously administering a further dose of 800 mg dose of intravenous ibuprofen about every six hours post-operatively to the patients at least until 24 hours after
surgery and about every 6 hours from about 24 hours after surgery up to about 5 days after surgery; and (iii) administering morphine, an opioid analgesic, post-operatively to the patients in an amount which is reduced by about 20% or more within the
first 24 hours after surgery than that typically required to control pain in human patients having undergone the same surgical procedure without said administration of ibuprofen, such that the human patients receiving intravenous ibuprofen experience
about a 30% reduction in mean morphine consumption.
2. The method of claim 1, wherein the patients experience a significant reduction in pain as measured by the VAS with movement and/or the VAS at rest area under the curve for time points within the first 24 hours after surgery.
3. The method of claim 1, provides a reduction in side effects associated with the administration of opioid analgesics.
4. The method of claim 1, wherein the patient undergoes a surgical procedure selected from orthopedic surgery, gynecologic surgery, major abdominal surgery, lower abdominal, and general investigative surgery.
5. The method of claim 1, wherein the ibuprofen being intravenously administered after surgery improves the time to ambulation and significantly reduces pain scores in the patients, as compared to such patients receiving opioid analgesics without said administration of ibuprofen.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.